Atezolizumab

5:44
Systemic therapies for advanced HCC
Arndt Vogel
4:05
Updates from IMbrave 150 in HCC
Daneng Li
3:56
Novel developments in HCC treatment
Daneng Li
3:33
ESMO WCGIC: highlights in HCC
Ghassan Abou-Alfa
5:42
Atezolizumab with radium-223 in metastatic castrate-resistant prostate cancer
Michael Morris
3:43
IMvigor010: atezolizumab for UC
Thomas Powles
7:09
Personalizing immunotherapy beyond PDL1 expression
Marleen Kok
17:02
The right biomarker for the right patient
Nicola Fusco
3:53
GELATO: carboplatin and atezolizumab in advanced lobular BC
Leonie Voorwerk
4:11
Immunotherapy for TNBC: IMpassion130 & KEYNOTE-355
Sara Tolaney
7:53
Growing treatment landscape for advanced bladder cancer
Cora Sternberg
0:56
Bladder cancer: combining IDO inhibitors with immunotherapy
Sima Porten
1:13
SAUL analysis: atezolizumab in urothelial carcinoma patients
Cora Sternberg
4:06
Bladder: neoadjuvant immunotherapy & ctDNA
Petros Grivas
1:48
Daniel Petrylak: GU 2020 prostate picks
Daniel Petrylak
2:03
3-factor model to predict response to atezolizumab
Guru Sonpavde
VJOncology VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals